Clinical effects of microtransplantation combined with antiangiogenic chemotherapy in treatment of non-small cell lung cancer

doi:10.3877/cma.j.issn.1674-0785.2017.22.003

Abstract

Abstract:

Objective

To evaluate the clinical efficacy and adverse reactions of microtransplantation combined with antiangiogenic chemotherapy in the treatment of patients with non-small cell lung cancer (NSCLC).

Methods

From January 2015 to May 2016, 104 patients with NSCLC treated at our hospital were divided into an observation group (51 cases) and a control group (53 cases). The observation group received microtransplantation combined with antiangiogenic chemotherapy, while the control group received antiangiogenic chemotherapy only. The short-term clinical effect, the rate of disease control, the quality of life, and adverse reactions were compared between the two groups.

Results

The effective rate in the observation group was significantly higher than that in the control group (70.6% vs 50.9, χ²=4.200, P<0.05). The disease control rate was also significantly higher in the observation group than in the control group (94.1% vs 81.1%, χ²=4.007, P<0.05). The rate of quality of life improvement was significantly higher in the observation group than in the control group (90.2% vs 75.5%, χ²=3.937, P<0.05). There was no significant difference in the rate of adverse reactions (including fever, gastrointestinal symptoms, liver and kidney dysfunction, and bone marrow suppression) between the two groups (P>0.05).

Conclusion

Microtransplantation combined with antiangiogenic chemotherapy can effectively improve the therapeutic effects and quality of life in patients with NSCLC.

Key words: Microtransplantation, Antiangiogenic chemotherapy, Non-small cell lung cancer

Xiaohua Feng, Baoping Li. Clinical effects of microtransplantation combined with antiangiogenic chemotherapy in treatment of non-small cell lung cancer[J]. Chinese Journal of Clinicians(Electronic Edition), 2017, 11(22): 2399-2402.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2017.22.003

https://zhlcyszz.cma-cmc.com.cn/EN/Y2017/V11/I22/2399

Figures/Tables 4

References 20

[1]	陈万青, 郑荣寿, 张思维, 等. 2013年中国恶性肿瘤发病和死亡分析 [J]. 中国肿瘤, 2017, 26(1): 1-7.
[2]	Rajasekaran T, Ng QS, Tan DS, et al. Metronomic chemotherapy: A relook at its basis and rationale [J]. Cancer Lett, 2017, 388: 328-333.
[3]	Guo M, Hu KX, Yu CL, et al. Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients [J]. Blood, 2011, 117(3): 936-941.
[4]	Guo M, Hu KX, Liu GX, et al. HLA-mismatched stem-cell microtransplantation as postremission therapy for acute myeloid leukemia:long-term follow-up [J]. J Clin Oncol, 2012, 30(33): 4084-4090.
[5]	李艳, 郭其森. 晚期非小细胞肺癌维持治疗进展 [J]. 中华肿瘤防治杂志, 2014, 21(10): 800-804.
[6]	陈雪曼, 宋尔卫. 肿瘤微环境与免疫治疗研究进展 [J]. 生物化学与生物物理进展, 2017, 44(8): 641-648.
[7]	Cazzaniga ME, Camerini A, Addeo R, et al. Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development [J]. Future Oncol, 2016 ,12(3): 373-387
[8]	BilBilir C, Durak S, Kizikaya B, et al. Efficacy of metronomic vinorelbine in elderly patients with advanced non-small-cell lung cancer and poor performance status [J]. Curr Oncol, 2017, 24(3): e199.
[9]	Karadurmus N, Sahin U, Basgoz BB, et al. Review of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in solid tumors excluding breast cancer [J]. World J Transplant, 2016, 6(4): 675-681.
[10]	Omazic B, Remberger M, Barkholt L, et al. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for solid cancer [J]. Biol Blood Marrow Transplant, 2015, 22(4): 676-681.
[11]	曹水, 王运良, 任宝柱, 等. 大剂量IL-2活化的HLA半相合异基因造血干细胞治疗10例晚期难治性肾癌的疗效观察 [J]. 中国肿瘤临床, 2011, 38(12): 712-715.
[12]	张利铭, 黄知平. 微移植——老年急性髓系白血病治疗新策略 [J]. 临床血液学杂志, 2014, 27(3): 368-370.
[13]	艾辉胜, 孙琪云. 《微移植治疗完全缓解期中青年急性髓细胞白血病的长期随访》解读 [J]. 临床血液学杂志, 2015, 28(3): 367-369.
[14]	吴惠惠, 刘铁强, 孙雪冬, 等. 白血病小鼠H-2全不相合微移植模型的建立及鉴定 [J]. 中国实验血液学杂志, 2014, 22(3): 779-784.
[15]	Guo M, Chao NJ, Li JY, et al. HLA-mismatched microtransplant in older patients newly diagnosed with acute myeloid leukemia: results from the microtransplantation interest group [J]. Jama Oncol, 2018, 4(1): 54-62.
[16]	David KA, Cooper D, Strair R. Clinical studies in hematologic microtransplantation [J]. Curr Hematol Malig Rep, 2017, 12(1): 51-60.
[17]	Zhu Y, Zhao H, Zhang X, et al. Decitabine before low-dose cytarabine-based chemotherapy combined with human leukocyte antigen–mismatched stem cell microtransplantation improved outcomes in elderly patients with newly diagnosed acute myeloid leukemia [J]. Biol Blood Marrow Transplant, 2017, 23(5): 830-835.
[18]	Hu KX, Sun QY, Guo M, et al. A study of human leukocyte antigen mismatched cellular therapy (stem cell microtransplantation) in high-risk myelodysplastic syndrome or transformed acute myelogenous leukemia [J]. Stem Cells Trans Med, 2016, 5(4): 524.
[19]	Tian H, Qu Q, Liu L, et al. Advances in Stem Cell Therapy for Leukemia [J]. Curr Stem Cell Res Ther, 2016, 11(2): 158-165.
[20]	Kong X, Chen Y, Wang LI, et al. Effect of the microtransplantation of allogeneic hematopoietic stem cells as maintenance therapy for elderly patients with acute leukemia [J]. Oncol Lett, 2015, 9(5): 2331-2334.

组别	例数	性别（男/女）	年龄（岁，±s）	病理分型（例，鳞癌/腺癌/其他）	肿瘤分期（Ⅲb期/Ⅳ期例）
微移植联合抗血管生成化疗组	51	31/20	65.6±10.6	6/32/13	10/41
单纯抗血管生成化疗组	53	31/22	66.1±9.4	6/30/17	13/40
统计值	?	χ²=0.057	t=0.298	χ²=0.560	χ²=0.365
P值	?	0.812	0.767	0.756	0.549

组别	例数	性别（男/女）	年龄（岁，±s）	病理分型（例，鳞癌/腺癌/其他）	肿瘤分期（Ⅲb期/Ⅳ期例）
微移植联合抗血管生成化疗组	51	31/20	65.6±10.6	6/32/13	10/41
单纯抗血管生成化疗组	53	31/22	66.1±9.4	6/30/17	13/40
统计值	?	χ²=0.057	t=0.298	χ²=0.560	χ²=0.365
P值	?	0.812	0.767	0.756	0.549

组别	例数	完全缓解	部分缓解	病变稳定	病变进展	有效率	疾病控制率
微移植联合抗血管生成化疗组	51	2（3.9）	34（66.7）	12（23.5）	3（5.9）	36（70.6）	48（94.1）
单纯抗血管生成化疗组	53	0（0）	27（50.9）	16（30.2）	10（18.9）	27（50.9）	43（81.1）
χ²值	?	-	-	-	-	4.200	4.007
P值	?	-	-	-	-	0.040	0.045

组别	例数	完全缓解	部分缓解	病变稳定	病变进展	有效率	疾病控制率
微移植联合抗血管生成化疗组	51	2（3.9）	34（66.7）	12（23.5）	3（5.9）	36（70.6）	48（94.1）
单纯抗血管生成化疗组	53	0（0）	27（50.9）	16（30.2）	10（18.9）	27（50.9）	43（81.1）
χ²值	?	-	-	-	-	4.200	4.007
P值	?	-	-	-	-	0.040	0.045

组别	例数	改善	稳定	下降	总改善率
微移植联合抗血管生成化疗组	51	30（58.8）	16（31.4）	5（9.8）	46（90.2）
单纯抗血管生成化疗组	53	21（39.6）	19（35.9）	13（24.5）	40（75.5）
χ²值	?	-	-	-	3.937
P值	?	-	-	-	0.047

Please choose a citation manager

Content to export